

TSVS 2026

09/05-06 @Taipei Marriott Hotel

台灣血管外科學會第十一屆第二次會員大會暨學術研討會

Sept. 5 (Saturday)

Venue: 主會場

0800-0810	Opening	孫坤理事長
Time	Topic (Speech Duration: 7 minutes)	Speaker
0810-0920	Vein 1-Varicose	
0810-0820	Future Tx for VV and current status in Korea	Insoo Park
0820-0830	Beyond Ablation: Optimizing Outcomes in Varicose Vein Treatment	Takahiro Imai
0830-0840	Perforator Tx: when and how?	Willy Yung-Wei Chi
0840-0850	Glue: more proximal & shallow?	柯博仁
0850-0900	Ambulatory phlebectomy: un-necessary	張學倫
0900-0910	Ambulatory phlebectomy: necessary	Wooshik Kim
Time	Topic (Speech Duration: 15 minutes)	Speaker
0920-1000	Vein 2-Keynote	
0920-0940	Venous-lymphatics biosignaling: from the lab to the best clinical practice	Sergio Giancesini
0940-1000	Current management of varicose vein in Japan: Technique of laser tributary ablation and safety analysis of cyanoacrylate closure	Makoto MO
Time	Topic (Speech Duration: 7 minutes)	Speaker
1000-1100	Vein 3-Deep Vein	
1000-1010	Mechanism of lower limb venous return	黃耀廣
1010-1020	Venous ulcer: deep or superficial first? 靜脈潰瘍：先處理深部還是淺部靜脈？	李秋陽
1020-1030	KTW syndrome: lifelong battle	Nuttawut Sermsathanasawad
1030-1040	Management of deep vein reflux: now and future (VAD & valve restoration)	林俊堯
1040-1050	Should we treat MTS/PTS earlier?	陳偉華
1050-1100	Management of CVI in Tropical Regions: Challenges and Adaptive Strategies	甘宗旦
1110-1150	Vein 4-Thrombosis	
1110-1120	Optimization of management of acute VTE	柯宏彥
1120-1130	Management and prevention of peripartum VTE	陳迪詠
1130-1140	Role of Aspiration thrombectomy in "endovascular first" approach for DVT: challenges, tips & tricks	Ismazizi Zaharudin
1140-1150	Update of anticoagulation strategy after venous intervention	李信賦
Time	Topic (Speech Duration: 7 minutes)	Speaker
1200-1300	GORE Luncheon Symposium	
	GORE TAG® Thoracic Branch Endoprosthesis	
1200-1205	Opening remarks	孫坤 理事長
1205-1225	Jikei Experiences	Takao Ohki
1225-1235	CGMH Experiences	鄭羽廷
1235-1245	VGH Experiences	陳泰位
1245-1255	Tri-Service Experiences	張瑞宗
1255-1300	Closing remarks	孫坤 理事長

Time	Topic (Speech Duration: 10 minutes)	Speaker
1300-1415	Aorta 1-Arch	
1300-1312	Reducing Procedural Risks of Aortic Arch Repair Through Customization: The Insights and Outcomes of CMD	Bijan Modarai
1312-1324	CMD Utilization for Arch Aneurysm and Abdominal Aorta: Clinical Practices in Taiwan from VGHTPE Experiences	陳沂名
1324-1336	Current Status and Future Promises of Innovative Branched Endografts for Arch Anomalies	Stephen WK Cheng
1336-1348	The Versatility of Retrograde In-Situ Branched Stentgrafting	Takao Ohki
1348-1400	Indications and Technical Nuances of Physician-Modified Endografts for Arch Pathologies	賴韋良
1400-1412	Surgical Strategies for Holistic Aortic Arch Reconstruction Utilizing Open Stent Grafts	Akihiro Yoshitake
1420-1535	Aorta 2-Complex Aneurysm: AAA and TAAA	
1420-1432	Clinical Benefits and Outcomes of Custom-Made Solutions in Overcoming TAAA Anatomical Barriers	Apinan Uthaipaisanwong
1432-1444	Tactical Planning and Execution of PMEG for Juxtarenal and Thoracoabdominal Aortic Repair	Chayatorn Chansakaow
1444-1456	Overcoming Anatomical Challenges in Abdominal Aortic Repair Utilizing Ultra Low Profile Devices	Nilo Javier Mosquera Arochena
1456-1508	Aortic Sac Management Strategies and Preemptive Embolization Techniques to Improve AAA Treatment Durability	Takuro Shirasu
1508-1520	Reevaluating Open Surgical Repair for AAA and TAAA in Current Endovascular Era	陳泰位
1520-1532	Confronting the Clinical Challenges of Redo Thoracoabdominal Aortic Repair	Susumu Oshima
1540-1715	Aorta 3-Aorta Dissection	
1540-1552	ATAAD Management and Clinical Realities in Taiwan: Is Further Improvement Possible	楊翔宇
1552-1604	Tailored False Lumen Obliteration Techniques in ATAAD Surgery: Lessons from a High-Volume Aortic Hospital	Suk-Won SONG
1604-1616	Strategic Mitigation of Distal Aortic New Entry and Malperfusion in ATAAD Management	Randolph Hung-leung WONG
1616-1628	Enhancing Anastomotic Reliability During Dissection Surgery Through Suture Techniques and Material Selection	Kensuke Ozaki
1628-1640	Timely TEVAR with Precision IVUS Guidance for Complicated and High Risk Uncomplicated TBAD	陳宇恆
1640-1652	Transcatheter Electrosurgical Aortic Septotomy Techniques for Complex TBAD Management	林寬傑
1652-1704	Prevention Over Intervention: Rationale of Renal Denervation for Post-Dissection Hypertension	顏旭霆
1830-1845	第十一屆第二次會員大會_TSVS Member Assembly	Venue: 主會場
1830-2100	Gala Dinner	Venue: 主會場

TSVS 2026

09/05-06 @Taipei Marriott Hotel

台灣血管外科學會第十一屆第二次會員大會暨學術研討會

Sept. 6 (Sunday)

Venue: 主會場

Time	Topic (Speech Duration: 7 minutes)	Speaker
------	--------------------------------------	---------

0830-1130	PAD 1	
-----------	--------------	--

0830-0840	Opening	
-----------	---------	--

0840-0850	Novel coronary screening for PAD patients: combine coronary and lower extremity CT angiography	Ayaka Yu
-----------	--	----------

0850-0900	Treatment of PAD patients with aortoiliac lesions: update on current evidence and guidelines	Ryoichi Kyuragi
-----------	--	-----------------

0900-0910	Treatment of PAD patients with femoropopliteal lesions: update on current evidence and guidelines	Kazunori Horie
-----------	---	----------------

0910-0920	Treatment of PAD patients with below-the-knee lesions: update on current evidence and guidelines	陳沂名
-----------	--	-----

0920-0940	Keynote speech: The role of distal bypass in the endovascular era	Nobuyoshi Azuma
-----------	--	-----------------

0940-1000	Discussion	
-----------	------------	--

1000-1010	Tea Break	
-----------	-----------	--

0830-1130	PAD 2	
-----------	--------------	--

1010-1020	The role of IVUS in PAD endovascular treatment	Kazunori Horie
-----------	--	----------------

1020-1030	Updated evidence for Sirolimus vs Paclitaxel Drug-Coated Balloons: Which Drug, Which Lesion, Which Patient?	EDWARD T C CHOKE
-----------	---	------------------

1030-1040	Conquer the calcium: debulking vs. IVL vs. scoring balloon	Kwong-shun CHAN
-----------	--	-----------------

1040-1050	Bioabsorbable stent for BTK endovascular treatment	李任光
-----------	--	-----

1050-1100	Cross, prepare, and treat: a synergic approach to complex CLI	Bruno Migliara
-----------	---	----------------

1100-1120	Discussion	
-----------	------------	--

1120-1130	Should endovascular therapy be the first shot for small wounds	陳宇恒
-----------	--	-----

1120-1130	Discussion	
-----------	------------	--

Time	Topic (Speech Duration: 7 minutes)	Speaker
------	--------------------------------------	---------

1200-1300	安健 Angeion Luncy Symposium	
-----------	-----------------------------------	--

1200-1205	Opening Remarks	孫坤 理事長
-----------	-----------------	--------

	Peripheral Session	
--	---------------------------	--

1205-1215	Large Randomized Trials Support the Utility of Sirolimus-Coated Balloon for PAD: SIRONA and SIRPAD Trials	黃玄禮
-----------	---	-----

1215-1225	FUTURE trial study, Taiwan experience and mid-term results	張兼華
-----------	--	-----

1225-1230	Q&A	
-----------	-----	--

	Aorta Session	
--	----------------------	--

1230-1240	Minos™ EVAR: Ultra-Low Profile Solutions for Complex AAA	顏旭霆
-----------	--	-----

1240-1250	Endovascular Repair of Aortic Arch: The Hector, Cratos and Talos	陳沂名
-----------	--	-----

1250-1255	Q&A	
-----------	-----	--

1255-1300	Closing Remarks	林佳勳
-----------	-----------------	-----

Time	Topic (Speech Duration: 7 minutes)	Speaker
1300-1430	PAD 3	
1300-1310	Hybrid treatment for PAD in Japan	Ayaka Yu
1310-1320	Is angiosome crucial for distal bypass	陳泰位
1320-1330	Our innovations in CLTI treatment	Hiroyoshi Komai
1330-1340	Revascularization in Patients with Diabetic Foot Ulcers: When is Limb Salvage Truly Achieved?	Tze-Woei TAN
1340-1350	Technical tips of bypass, completion angiography and graft flow evaluation	Shinsuke Kikuchi
1350-1400	Revascularization Strategies in CLTI Patients Without an Adequate Single-Segment Saphenous Vein	Takuro Shirasu
1400-1410	Could bypass vein graft be remodeling by balloon just like fistula	李應陞
1410-1420	Discussion	
1430-1550	Merit: Pave the way for uremic patients with occluded central vein	
	Hemodialysis access strategy with occluded central vein.	
	Open bypass	
	Endovascular bypass: cover stent, bare metal stent, Hero graft,	
	Permanent catheter	

鄭永強醫生個人簡歷

個人資料

姓名：鄭永強醫生

職稱：教授、顧問醫生

所屬機構：香港大學李嘉誠醫學院、香港瑪麗醫院

專科：血管外科

教育背景

- 香港大學內外全科醫學士（MBBS）
- 英國愛丁堡皇家外科醫學院院士（FRCS Edin）
- 香港外科醫學院院士（FHKCS）
- 香港大學醫學博士（MD）

專業資格與認證

- 香港醫務委員會註冊專科醫生（外科）
- 英國皇家外科醫學院榮譽院士
- 亞洲血管外科學會會員
- 國際血管外科學會會員

工作經驗

現任職位

- 香港大學李嘉誠醫學院 外科學系教授
- 香港瑪麗醫院 血管外科顧問醫生
- 香港大學深圳醫院 血管外科名譽顧問

曾任職位

- 香港大學外科學系助理教授
- 瑪麗醫院外科駐院醫生及高級駐院醫生
- 香港血管外科學會秘書及司庫

專業專長

- 周邊血管疾病診斷與治療
- 主動脈瘤及主動脈夾層手術
- 頸動脈內膜切除術
- 下肢動脈閉塞症介入治療
- 靜脈曲張微創手術
- 透析通路建立與維護

學術成就

研究領域

- 動脈硬化閉塞症的病理機制
- 血管移植物的生物相容性研究
- 微創血管介入技術的臨床應用
- 血管疾病患者的長期預後分析

學術發表

- 在國際知名醫學期刊發表學術論文逾 100 篇
- 參與編寫血管外科專科教材及臨床指南
- 多次在國際血管外科會議擔任講者

專業服務

學會職務

- 香港血管外科學會委員
- 亞洲血管外科學會理事
- 世界血管外科學會委員

審稿工作

- 多個國際血管外科期刊審稿人
- 醫學研究基金申請評審專家

獎項與榮譽

- 香港大學優秀教學獎
- 亞洲血管外科傑出貢獻獎
- 國際血管外科會議最佳論文獎
- 香港醫學專科学院傑出會員

語言能力

- **中文：**母語（廣東話、普通話）
- **英文：**流利
- **書寫：**繁體中文、英文

Dr. Wooshik Kim MD



Professional Affiliations & Positions

Board Member, Korean Society for Phlebology
Chair, Academic Committee, Korean Society for Phlebology
Member, Ultrasound Committee, Korean Society for Thoracic and Cardiovascular Surgery
Secretary General, Varicose Vein Research Society, Korean Society for Thoracic and Cardiovascular Surgery
Secretary General, History and Archives Committee, Korean Society for Thoracic and Cardiovascular Surgery
Executive Member, ECMO Research Society, Korean Society for Thoracic and Cardiovascular Surgery
Member, New Health Technology Assessment Committee
Member, Humidifier Disinfectant Expert Committee
Member, COVID-19 Vaccination Injury Compensation Advisory Committee
Member, Institutional Advisory Committee, Korea Institute for Healthcare Accreditation
Head of Thoracic Surgery, National Medical Center (Current)

Present Hospital Appointment

Thoracic Surgeon, National Medical Center (since April 2005 – Present)

Medical Training

M.D., Wonkwang University College of Medicine, 2000
Internship & Residency in Thoracic Surgery, National Medical Center, 2005
M.S. & Ph.D., Graduate School, The Catholic University of Korea, 2018–2023

Fellowships & Observerships

Lunds Malmö University Hospital, Sweden (Short-term Training, Jun 2007)
Samsung Medical Center Cancer Center, Thoracic Surgery (Nov 2009 – Jan 2010)
University Hospital Regensburg, ECMO Center, Germany (Sep 2015)
Shanghai Pulmonary Hospital, China (Nov 2018)
Duke University Medical Center, Thoracic Surgery, USA (Mar 2019 – Feb 2020)
Karolinska University Hospital, Sweden (Apr 2024 – Jun 2024)

Society Memberships

Lifetime Member, Korean Society for Thoracic and Cardiovascular Surgery
Member, Society of Thoracic Surgeons (STS)
Member, European Society of Thoracic Surgeons (ESTS)
Member, Asian Society for Cardiovascular and Thoracic Surgery (ASCVTS)
Member, Korean Society for Vascular Surgery
Member, European Society for Vascular Surgery (ESVS)
Member, Korean Society for Phlebology
Member, American Vein and Lymphatic Society (AVLS)

Topic title suggestions and abstracts:

1. Contemporary Endovascular Management of the Left Subclavian Artery in Thoracic and Thoracoabdominal Aortic Repair

This presentation will review contemporary strategies for preserving left subclavian artery perfusion during endovascular repair of thoracic and thoracoabdominal aortic aneurysms. It will focus on patient and anatomical selection, procedural planning, and the relative roles of branched and fenestrated endografts, including custom made and off the shelf solutions. Technical considerations, limitations, complications and current clinical outcomes and the evolving place of total endovascular left subclavian artery incorporation in complex aortic repair will be discussed.

2. European Aortic Data Collection Registry: Contemporary Outcomes in Extent IV Thoracoabdominal, Pararenal and Juxtarenal Aortic Disease

This presentation will provide an update from the European Aortic Data Collection Registry on the real world use of custom made fenestrated and branched endografts in 701 patients with extent IV thoracoabdominal, pararenal, paravisceral or juxtarenal aortic disease. Outcomes in 270 patients with extent IV thoracoabdominal, pararenal or paravisceral disease will be compared with those in 431 patients with juxtarenal disease. The talk will examine patient characteristics, device configurations, procedural performance and early clinical outcomes, including technical success, target vessel incorporation, mortality, spinal cord ischaemia, renal complications, endoleak, branch occlusion and secondary intervention. It will also consider what these multicentre European data indicate about the safety, reproducibility and current limitations of complex endovascular aortic repair.

3. Custom Endograft Design in Chronic Aortic Dissection: Anatomy, Planning Data, and Evolving Practice

This presentation will review the latest evidence and design rationale for custom made endovascular grafts in chronic aortic dissection, drawing on the speaker's clinical experience, a transatlantic multicenter B/FEVAR registry, and evolving planning-center data. Emphasis is placed on tailoring graft configurations to each patient's anatomy, particularly true lumen caliber at key aortic levels and the alignment of celiac, mesenteric, and renal arteries. Emerging trends include a shift toward greater use of directional branches (over fenestrations) to accommodate complex visceral anatomies, supported by recent series in which 917 visceral vessels were revascularized using 63% fenestrations and 37% branches. The talk also highlights the growing role of staged interventions (e.g. proximal TEVAR followed by a distal custom branched/fenestrated repair after interval imaging) to allow true lumen expansion and optimal planning. Taken together, these data illustrate how anatomy driven device design and procedural staging have evolved in chronic aortic dissection, defining the anatomical and procedural boundaries for customisation and informing whether standardised branched platforms could be considered in carefully selected patients.

4. Does EVAR Increase Cancer Risk? Answers from national data analysis

This talk presents the latest analysis of a nationwide cohort study (90,000 patients) on cancer incidence after abdominal aortic aneurysm repair, comparing endovascular repair (EVAR) with open surgical repair. EVAR patients showed a marked increase in liver cancer incidence relative to open repair. I will discuss radiation exposure during EVAR as a potential contributor, EVAR patients undergo substantial cumulative radiation from intraoperative fluoroscopy and follow-up imaging, which can induce DNA damage and chromosomal aberrations. Prior studies on radiation dose and oncologic risk will be reviewed to contextualize our findings. The talk concludes with a cautious interpretation, emphasizing the need for prospective radiation tracking and long-term patient surveillance to further clarify any causal links and to ensure patient safety.

5. Custom made Fenestrated and branched options for urgent cases and/or unusual anatomies

This presentation will examine the range of fenestrated and branched endovascular options available for urgent aortic repair and anatomies that fall outside conventional device pathways. Through a series of complex cases, it will address arch branch repair for an expanding anastomotic pseudoaneurysm, treatment of aneurysmal degeneration involving the visceral segment after previous thoracic and infrarenal repair, emergency management of a symptomatic visceral patch aneurysm after open thoracoabdominal repair, and rupture in a patient with hostile access and severe aortoiliac tortuosity. The discussion will focus on device selection and configuration, including inner branches, fenestrations and off label adaptations; the balance between open and endovascular repair; procedural urgency; access strategy; spinal cord and visceral perfusion; and the technical and clinical compromises required when ideal planning time is unavailable.

Bijan Modarai PhD FRCS

King's Health Partners Professor of Surgery
Director of the King's Centre for Academic Surgery

Professor Bijan Modarai is a vascular surgeon scientist at King's College London and a Consultant Vascular and Endovascular Surgeon at Guy's and St Thomas' NHS Foundation Trust since 2012. In 2026 he was appointed as the King's Health Partners Professor of Surgery and Director of the King's Centre for Academic Surgery. He is recognised as a key opinion leader for management of complex aortic disease, including endovascular aortic repair, reflected by an extensive invited lecture portfolio, and leadership of major international scientific initiatives. He directs the Interdisciplinary Aortic Dissection Symposium, an established international forum for addressing unresolved challenges in aortic disease. He has chaired the European Society for Vascular Surgery radiation protection guidelines committee and continues to contribute to international guideline development and consensus activity. He is a past President of the British Society of Endovascular Therapy.

He has held successive fellowships from the British Heart Foundation from PhD through Intermediate and Senior Clinical Research Fellowships to Programme Grant level funding. He was awarded a Hunterian Professorship by The Royal College of Surgeons of England in 2017. He currently leads major translational programmes spanning vascular biology, imaging science, computational modelling and data enabled research, leveraging international multidisciplinary collaborative teams. His work on pro-angiogenic monocytes has defined a novel therapeutic target in limb ischaemia and progressed from mechanistic studies to early phase clinical trials. In parallel, he has developed innovative imaging and computational approaches to aortic disease.

He is Director of the King's Centre for Doctoral Training in Translational Research in Advanced Therapies, leading a cross-disciplinary PhD training programme. He has established the King's Cardiovascular Biobank, creating a critical platform for linking biological samples with clinical and imaging data at scale. He is Head of Section and Clinical Theme Lead for the School of Cardiovascular and Metabolic Medicine & Sciences, where he has driven integration between research and clinical strengths.